BrainsWay (NASDAQ:BWAY) Announces Quarterly Earnings Results, Beats Estimates By $0.03 EPS

BrainsWay (NASDAQ:BWAY) issued its quarterly earnings data on Tuesday. The company reported $0.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.01 by $0.03, Zacks reports. BrainsWay had a net margin of 3.88% and a return on equity of 3.56%. The firm had revenue of $10.50 million during the quarter, compared to analysts’ expectations of $10.07 million. During the same period last year, the company earned ($0.01) earnings per share. BrainsWay updated its FY 2024 guidance to EPS.

BrainsWay Price Performance

Shares of NASDAQ:BWAY traded down $0.70 during midday trading on Wednesday, reaching $9.00. 162,746 shares of the company’s stock were exchanged, compared to its average volume of 95,673. The stock has a market cap of $150.12 million, a price-to-earnings ratio of 91.01 and a beta of 1.25. The firm’s 50 day simple moving average is $9.11 and its two-hundred day simple moving average is $7.40. BrainsWay has a fifty-two week low of $3.80 and a fifty-two week high of $10.98.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the company. HC Wainwright reissued a “buy” rating and issued a $16.00 target price on shares of BrainsWay in a research note on Monday, October 21st. Northland Securities increased their target price on BrainsWay from $11.00 to $12.50 and gave the company an “outperform” rating in a report on Thursday, October 3rd.

About BrainsWay

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.